- Previous Close
77.90 - Open
78.01 - Bid 79.37 x --
- Ask 79.47 x --
- Day's Range
77.90 - 79.70 - 52 Week Range
38.56 - 100.80 - Volume
424,203 - Avg. Volume
1,162,448 - Market Cap (intraday)
43.502B - Beta (5Y Monthly) 1.49
- PE Ratio (TTM)
31.38 - EPS (TTM)
2.53 - Earnings Date Jan 29, 2025 - Feb 3, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Sep 18, 2002
- 1y Target Est
--
Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), formulations, and home health products in India, the United States, and internationally. The company offers APIs for anti-histaminic, anti-asthmatic, anti-lipemic, anti-hypertensive, anti-diabetic, anti-coagulant, anti-gout, anti-depressant, and anti-malarial drugs; and home diagnostic products, such as air purifiers, sphygmomanometer, blood glucose test strips, blood pressure monitors, breathe free vaporizers, stethoscopes, digital thermometers, blood glucose monitors, nebulizers, heat belts, and pulse oximeters. It also provides fever X for fever; Pain X for pain; Fiber-X, a sat isabgol; Acidity X for acidity; Burnol, first degree/minor burns cream; and formulations for nutrition and probiotics, gastroenterology, antibiotics, gynecology, anti-allergic, and central nervous system, as well as cardiology, diabetology, and nutraceuticals. The company offers over the counter products under the Dr. Morepen brand. Morepen Laboratories Limited was incorporated in 1984 and is based in Gurugram, India.
www.morepen.com2,152
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: MOREPENLAB.BO
View MorePerformance Overview: MOREPENLAB.BO
Trailing total returns as of 11/29/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MOREPENLAB.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MOREPENLAB.BO
View MoreValuation Measures
Market Cap
42.69B
Enterprise Value
40.98B
Trailing P/E
30.79
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.31
Price/Book (mrq)
3.84
Enterprise Value/Revenue
2.34
Enterprise Value/EBITDA
19.39
Financial Highlights
Profitability and Income Statement
Profit Margin
7.40%
Return on Assets (ttm)
8.31%
Return on Equity (ttm)
13.88%
Revenue (ttm)
17.75B
Net Income Avi to Common (ttm)
1.31B
Diluted EPS (ttm)
2.53
Balance Sheet and Cash Flow
Total Cash (mrq)
1.86B
Total Debt/Equity (mrq)
3.02%
Levered Free Cash Flow (ttm)
-669.34M